Table 2 Patient clinical characteristics
Training cohort (n = 70) | Validation cohort (n = 30) | Univariate analysis in the training cohort | Multivariate analysis in the training cohort | |||
|---|---|---|---|---|---|---|
OR (n = 35) | NR (n = 35) | P value | P value | |||
Treatment response (OR:NR) | 35:35 | 15:15 | / | / | / | / |
Age | 63.2 ± 11.8 | 61.6 ± 9.3 | 63.3 ± 11.7 | 63.0 ± 12.1 | 0.895 | |
Sex (M:F) | 48:22 | 25:5 | 21:14 | 27:8 | 0.126 | |
AFP(>15ng/ml) | 26 | 7 | 10 | 16 | 0.141 | |
hCRP(mg/L) | 2.18 (0.78 ~ 10.45) | 2.14 (0.94 ~ 7.21) | 1.85 (0.76 ~ 5.84) | 4.14 (0.96 ~ 21.32) | 0.012 | 0.033 |
ALT(> 50U/L) | 10 | 3 | 5 | 5 | 1.000 | |
AST(> 40U/L) | 19 | 7 | 9 | 10 | 0.788 | |
GGT(> 60U/L) | 25 | 10 | 10 | 15 | 0.215 | |
ALP(> 125U/L) | 25 | 10 | 10 | 15 | 0.215 | |
TBIL(> 17.1umol/L) | 35 | 21 | 14 | 21 | 0.097 | |
DBIL(> 6.84umol/L) | 21 | 10 | 7 | 14 | 0.072 | |
IBIL(> 12umol/L) | 39 | 21 | 17 | 22 | 0.231 | |
With history of chronic liver disease | 61 | 27 | 31 | 30 | 0.722 | |
BCLC (A:B) | 55:15 | 23:7 | 31:4 | 24:11 | 0.049 | |
Therapy method (TACE:RFA) | 46:24 | 23:7 | 18:17 | 28:7 | 0.014 | 0.048 |